SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand

SeaStar Medical Holding

12/08/2026 21:21

Overview
US organ failure therapy firm's Q2 net revenue rose 82% yr/yr on increased QUELIMMUNE demand
Q2 net loss widened yr/yr due to higher R&D and administrative expenses
Company advanced adult AKI trial enrollment and obtained new hospital billing codes for SCD therapy

Outlook
SeaStar Medical expects to complete NEUTRALIZE-AKI trial enrollment around year end or into Q1 2027
Company says new ICD-10-PCS codes for SCD therapies take effect October 1, 2026
SeaStar Medical sees continued QUELIMMUNE revenue growth and potential in larger adult AKI market

Result Drivers
QUELIMMUNE EXPANSION - Addition of three top-rated children's hospitals and increased customer orders drove Q2 net revenue growth
CLINICAL TRIAL COSTS - Higher research and development expenses were primarily driven by increased clinical trial expenses and personnel costs
NEW BILLING CODES - Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for SCD therapy, including QUELIMMUNE

Company press release: ID:nGNX4DbvLk

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.91
 
Q2 Net Loss
 
$3.73 mln
 
Q2 Operating Expenses
 
$4.35 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $10.00, about 171% above its August 11 closing price of $3.69

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 11 - CalciMedica Q2 net loss widens
Aug 10 - Vera Therapeutics Q2 loss widens less than expected

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)